Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries.

× No keyword cloud information.

26 in total

1. Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.

Authors: Kelly E Dooley; Anne F Luetkemeyer; Jeong-Gun Park; Reena Allen; Yoninah Cramer; Stephen Murray; Deborah Sutherland; Francesca Aweeka; Susan L Koletar; Florence Marzan; Jing Bao; Rada Savic; David W Haas
Journal: Antimicrob Agents Chemother Date: 2014-06-23 Impact factor: 5.191

2. Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention.

Authors: R Kajubi; L Huang; P Jagannathan; N Chamankhah; M Were; T Ruel; C A Koss; A Kakuru; N Mwebaza; M Kamya; D Havlir; G Dorsey; P J Rosenthal; F T Aweeka
Journal: Clin Pharmacol Ther Date: 2017-05-30 Impact factor: 6.875

3. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors: George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal: Pediatr Infect Dis J Date: 2013-11 Impact factor: 2.129

4. Anti-HIV and Anti-Hepatitis C Virus Drugs Inhibit P-Glycoprotein Efflux Activity in Caco-2 Cells and Precision-Cut Rat and Human Intestinal Slices.

Authors: Ondrej Martinec; Martin Huliciak; Frantisek Staud; Filip Cecka; Ivan Vokral; Lukas Cerveny
Journal: Antimicrob Agents Chemother Date: 2019-10-22 Impact factor: 5.191

5. Computational pharmacokinetics/pharmacodynamics of rifampin in a mouse tuberculosis infection model.

Authors: Michael A Lyons; Anne J Lenaerts
Journal: J Pharmacokinet Pharmacodyn Date: 2015-05-31 Impact factor: 2.745

Review 6. Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment.

Authors: Yuqing Gong; Sanjana Haque; Pallabita Chowdhury; Theodore J Cory; Sunitha Kodidela; Murali M Yallapu; John M Norwood; Santosh Kumar
Journal: Expert Opin Drug Metab Toxicol Date: 2019-04-20 Impact factor: 4.481

7. Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc.

Authors: Olga Latinovic; Janaki Kuruppu; Charles Davis; Nhut Le; Alonso Heredia
Journal: Clin Med Ther Date: 2009

8. Computational pharmacology of rifampin in mice: an application to dose optimization with conflicting objectives in tuberculosis treatment.

Authors: Michael A Lyons
Journal: J Pharmacokinet Pharmacodyn Date: 2014-08-31 Impact factor: 2.745

9. Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection.

Authors: Kelly E Dooley; Paolo Denti; Neil Martinson; Silvia Cohn; Fildah Mashabela; Jennifer Hoffmann; David W Haas; Jennifer Hull; Regina Msandiwa; Sandra Castel; Lubbe Wiesner; Richard E Chaisson; Helen McIlleron
Journal: J Infect Dis Date: 2014-07-31 Impact factor: 5.226

10. Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children.

Authors: Shereen Katrak; Anne Gasasira; Emmanuel Arinaitwe; Abel Kakuru; Humphrey Wanzira; Victor Bigira; Taylor G Sandison; Jaco Homsy; Jordan W Tappero; Moses R Kamya; Grant Dorsey
Journal: Malar J Date: 2009-11-30 Impact factor: 2.979